The study, published December 5 in the Proceedings of the National Academy of Sciences, highlights the importance of vaccination for preventing the spread of HPV in young men before they become sexually active. Vaccination could potentially prevent reinfection in older men who have already contracted the virus.
US Food and Drug Administration (FDA) Commissioner Scott Gottlieb and NIH Director Francis Collins testified on Thursday before the House Energy & Commerce Committee on how their agencies have worked to implement provisions from the 21st Century Cures Act passed and signed by President Barack Obama a month before he left office.
The Prostate Health Index (phi) (Beckman Coulter) significantly changes urologists' opinions about whether men with certain results on prostate-specific antigen (PSA) screening should or should not undergo a prostate biopsy to assess for cancer, according to new observational research.
While Zika virus causes devastating damage to the brains of developing fetuses, it one day may be an effective treatment for glioblastoma, a deadly form of brain cancer. New research from Washington University School of Medicine in St. Louis and the University of California San Diego School of Medicine shows that the virus kills brain cancer stem cells, the kind of cells most resistant to standard treatments.
Metastatic cancer is responsible for the vast majority of cancer deaths, but our limited understanding of how metastasis begins makes finding ways to stop it hugely challenging. A new study may provide some insight, however.
Researchers at Stanford University School of Medicine with the National Cancer Institute (NCI) have identified another cancer-surface molecule, CD22, and begun trials on B-cell acute lymphoblastic leukemia (ALL) patients using an immuno-oncology approach similar to CAR-T. In the Phase I trial, 15 of the 21 patients who had previously relapsed or did not respond to anti-CD19 CAR-T, were treated with an anti-CD22 CAR-T therapy. Ten of the 15 patients had already received treatment for CD19-targeted treatment.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.